Its disappointing that Pfizer is not able to find marketing leverage for Vascepa in Canada primary care ! How will this impact evaluation estimates for other BP's in Europe ?? Its most likely a Bearish sign, neutral at best, and not what I was hoping for !!
Market Data 
Markets 
AI
